Phathom Reports P-III Study (PHALCON-NERD-301) Results of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Shots:
- The initial 4wk. results from the P-III study (PHALCON-NERD-301) evaluating vonoprazan (10/20mg, qd) vs PBO in 776 patients with sGERD or NERD. The trial also includes a 20wk. long-term extension period
- The trial met its 1EPs i.e., vonoprazan (10/20mg) showed a greater percentage of 24hr. heartburn-free days (46.4%/46.0% vs 27.5%) with a median percentage of (48.3%/46.7% vs 17.0%), respectively, were well tolerated, and overall AEs were consistent with the prior study. The results are expected to be presented in 2023
- The company is currently in talks with the US FDA about a different P-III trial design to assess the novel dosing regimen for vonoprazan to treat episodic heartburn in patients with symptomatic NERD
Ref:Globe Newswire | Image: Phathom Pharmaceuticals
Related News:- Phathom’s Voquezna Triple PAK & Voquezna Dual PAK Receives the US FDA’s Approval for the Treatment of H. pylori Infection in Adults
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
